Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes
Main finding · PAD surgical eventsResult — go to the resultAdjusted hazard ratio 1.18 95% CI 1.08–1.29Authors' conclusion
SGLT2i as an add-on diabetes therapy was associated with an increased cause-specific hazard of PAD surgeries compared with DPP-4i.
Study context
- Population
- US veterans aged ≥18 years with diabetes receiving Veterans Health Administration care, 2000–2021; median age 69 years, median HbA1c 8.4%, median diabetes duration 10.1 yearsuse episodes, weighted cohort
- Participants
- 76,072 vs 75,833
- Exposure
- SGLT2i vs DPP-4i as add-on therapy
- SGLT2in = 76,072
- DPP-4in = 75,833reference
- Outcome
- Composite peripheral artery disease (PAD) surgical outcome:
- Peripheral revascularization
- Amputation procedures
- Follow-up
- Events up to 90 days after stopping
Methodological detailspropensity score-weighted, new-user design, competing risk of death
- Propensity score-weighted
- New-user design
- Competing risk of death
Main finding
PAD surgical events
Adjusted hazard ratio
1.18
95% CI 1.08–1.29
Events by group
SGLT2i
11.2 per 1,000 person-years
874 of 76,072
DPP-4i
10.0 per 1,000 person-years
780 of 75,833
SGLT2ivs DPP-4i
aHR 1.18 (95% CI 1.08–1.29)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | |
|---|---|---|
| PAD events allowed up to 360 days after SGLT2i use ended · 360 days after stopping | 1.16 (1.06–1.26) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Use of SGLT2i Versus DPP-4i as an Add-on Therapy and the Risk of PAD-Related Surgical Events (Amputation, Stent Placement, or Vascular Surgery): A Cohort Study in Veterans With Diabetes. Diabetes Care. Published 2 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →